Jiangsu Changyou Environmental Protection Technology
301557
Hefei conver Holding
603409
LIERDA
832149
4
SHENGNAN TECHNOLOGY
837006
5
CHK
831167
CN Stock MarketDetailed Quotes
002581 Shandong Sinobioway Biomedicine
- 10.31
- -0.11-1.06%
Market Closed Mar 4 15:00 CST
6.80BMarket Cap-19.56P/E (TTM)
10.50High10.11Low183.91KlotVolume10.25Open10.42Pre Close188.84MTurnover4.59%Turnover RatioLossP/E (Static)659.74MShares14.4352wk High3.25P/B4.13BFloat Cap7.7952wk Low11.46Limit Up400.79MShs Float71.85Historical High9.38Limit Down3.74%Amplitude4.39Historical Low--Dividend TTM10.27Avg Price99.89KlotAsk--Div YieldTTM100Lot Size80.04KlotBid
Shandong Sinobioway Biomedicine News
Unnamed Pharmaceuticals: 2024 Annual Results Forecast
Unnamed Medicine: Announcement of Resolutions of the 33rd Meeting of the Fifth Board of Directors
Unnamed Pharmaceuticals: Announcement on the completion of the 2024 Stock Option Incentive Plan grant
Unnamed Medicine: Announcement on the intention to sign the “General Contracting Contract for Construction Projects”
Unnamed Medicine: Announcement of Resolutions of the 32nd Meeting of the Fifth Board of Directors
Unnamed Medicine: Announcement on the Proposed Signing of the “Technical Service Agreement for Drug Clinical Trials”
Unnamed Pharmaceuticals: Announcement on capital increase to wholly-owned subsidiary
Unnamed Pharmaceuticals: Announcement on Granting Stock Options to Incentive Recipients of the Company\'s 2024 Stock Options Incentive Plan
Unnamed Pharmaceuticals: Supervisory Board\'s Review Opinions on the List of Incentive Recipients Granted by the Company\'s 2024 Stock Option Incentive Plan
Unnamed Medicine: Announcement of Resolutions of the 31st Meeting of the Fifth Board of Directors
Unnamed Medicine: Legal Opinion of Zhejiang Tianzu (Shenzhen) Law Firm on the awarding of the 2024 Stock Option Incentive Plan for Shandong Weiming Biomedical Co., Ltd.
Unnamed Medicine: Announcement of Resolutions of the 21st Meeting of the Fifth Board of Supervisors
Unnamed Pharmaceuticals: Announcement of Resolutions of the 2024 Fourth Extraordinary General Meeting of Shareholders
Unnamed Pharmaceuticals: Self-inspection Report on the 2024 Stock Options Incentive Plan: Insider Information Insiders and Incentive Targets to Trade Company Shares
Unnamed Medicine: Legal Opinion of Zhejiang Tianze (Shenzhen) Law Firm on the 2024 Fourth Extraordinary General Meeting of Shareholders of Unnamed Medicine
Unnamed Pharmaceuticals: Explanation and Verification Opinions of the Supervisory Board on the Publication of the Company\'s 2024 Stock Option Incentive Plan Incentive List
Unnamed Pharmaceuticals: Announcement on the progress of the transfer of shares in participating companies through public listing
Unnamed Pharmaceuticals: Announcement on the Change of Chief Financial Officer
Unnamed Medicine: Announcement of Resolutions of the 30th Meeting of the Fifth Board of Directors
Unnamed Pharmaceuticals: An indicative announcement on the adoption of an autonomous exercise model during the first exercise period of the 2023 Stock Options Incentive Plan